Immunotherapy in mucosal melanoma: a case report and review of the literature.

about

Immunotherapy in mucosal melanoma: a case report and review of the literature.

Item

http://www.wikidata.org/entity/Q55053720

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Immunotherapy in mucosal melanoma: a case report and review of the literature.

@en

Immunotherapy in mucosal melanoma: a case report and review of the literature.

@nl

type

Item

label

Immunotherapy in mucosal melanoma: a case report and review of the literature.

@en

Immunotherapy in mucosal melanoma: a case report and review of the literature.

@nl

prefLabel

Immunotherapy in mucosal melanoma: a case report and review of the literature.

@en

Immunotherapy in mucosal melanoma: a case report and review of the literature.

@nl

P1476

Immunotherapy in mucosal melanoma: a case report and review of the literature.

@en

P2093

Bohuslav Melichar

http://www.w3.org/2001/XMLSchema#string

David Vrana

http://www.w3.org/2001/XMLSchema#string

Hana Kalabova

http://www.w3.org/2001/XMLSchema#string

Hana Studentova

http://www.w3.org/2001/XMLSchema#string

Karin Chytilova

http://www.w3.org/2001/XMLSchema#string

Ladislava Kucerova

http://www.w3.org/2001/XMLSchema#string

Pavel Koranda

http://www.w3.org/2001/XMLSchema#string

P2860

New perspectives on the role of vitiligo in immune responses to melanoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Distinct sets of genetic alterations in melanoma

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.

Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.

Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis.

Ipilimumab for patients with advanced mucosal melanoma.

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

P304

17971-17977

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.18632/ONCOTARGET.24727

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29707161

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5915169

http://www.w3.org/2001/XMLSchema#string